BPH Global Ltd - Asset Resilience Ratio

Latest as of June 2023: 33.28%

BPH Global Ltd (BP8) has an Asset Resilience Ratio of 33.28% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BPH Global Ltd (BP8) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$630.00K
≈ $445.77K USD Cash + Short-term Investments

Total Assets

AU$1.89 Million
≈ $1.34 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how BPH Global Ltd's Asset Resilience Ratio has changed over time. See BPH Global Ltd net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down BPH Global Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BPH Global Ltd (BP8) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$630.00K 33.28%
Total Liquid Assets AU$630.00K 33.28%

Asset Resilience Insights

  • Very High Liquidity: BPH Global Ltd maintains exceptional liquid asset reserves at 33.28% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

BPH Global Ltd Industry Peers by Asset Resilience Ratio

Compare BPH Global Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Drug Manufacturers - Specialty & Generic 43.05%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
Drug Manufacturers - Specialty & Generic 24.59%
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
Drug Manufacturers - Specialty & Generic 31.63%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 3.29%

Annual Asset Resilience Ratio for BPH Global Ltd (2016–2023)

The table below shows the annual Asset Resilience Ratio data for BPH Global Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-06-30 29.99% AU$630.83K
≈ $446.35K
AU$2.10 Million
≈ $1.49 Million
+20.99pp
2022-06-30 8.99% AU$685.56K
≈ $485.08K
AU$7.62 Million
≈ $5.39 Million
-47.94pp
2021-06-30 56.93% AU$5.26 Million
≈ $3.72 Million
AU$9.23 Million
≈ $6.53 Million
-28.68pp
2020-06-30 85.61% AU$866.83K
≈ $613.34K
AU$1.01 Million
≈ $716.46K
+7.41pp
2019-06-30 78.19% AU$1.90 Million
≈ $1.35 Million
AU$2.43 Million
≈ $1.72 Million
+9.51pp
2018-06-30 68.69% AU$1.09 Million
≈ $768.68K
AU$1.58 Million
≈ $1.12 Million
+29.01pp
2017-06-30 39.67% AU$1.04 Million
≈ $739.09K
AU$2.63 Million
≈ $1.86 Million
+39.32pp
2016-06-30 0.35% AU$17.14K
≈ $12.13K
AU$4.88 Million
≈ $3.45 Million
--
pp = percentage points

About BPH Global Ltd

AU:BP8 Australia Drug Manufacturers - Specialty & Generic
Market Cap
$2.62 Million
AU$3.71 Million AUD
Market Cap Rank
#29386 Global
#1723 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.00
All Time High
AU$2.05
About

BPH Global Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia. The company's products include raw bird's nest and processed bird's nest products, and Caulerpa Lentillifera, sea grapes and seaweeds. Its products are used in the food, nutrition, healthcare, health supplements, cosmetics… Read more